280 related articles for article (PubMed ID: 33068777)
1. DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Bittel A; Maruyama R; Echigoya Y; Nguyen Q; Huang Y; Dzierlega K; Zhang A; Chen YW; Yokota T
Mol Ther; 2021 Feb; 29(2):848-858. PubMed ID: 33068777
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of
Lim KRQ; Maruyama R; Echigoya Y; Nguyen Q; Zhang A; Khawaja H; Sen Chandra S; Jones T; Jones P; Chen YW; Yokota T
Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16509-16515. PubMed ID: 32601200
[TBL] [Abstract][Full Text] [Related]
3. Knocking Down DUX4 in Immortalized Facioscapulohumeral Muscular Dystrophy Patient-Derived Muscle Cells.
Lim KRQ; Yokota T
Methods Mol Biol; 2023; 2587():197-208. PubMed ID: 36401032
[TBL] [Abstract][Full Text] [Related]
4. Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics.
Chen JC; King OD; Zhang Y; Clayton NP; Spencer C; Wentworth BM; Emerson CP; Wagner KR
Mol Ther; 2016 Aug; 24(8):1405-11. PubMed ID: 27378237
[TBL] [Abstract][Full Text] [Related]
5. Improving Molecular and Histopathology in Diaphragm Muscle of the Double Transgenic ACTA1-MCM/FLExDUX4 Mouse Model of FSHD with Systemic Antisense Therapy.
Lu-Nguyen N; Malerba A; Antoni Pineda M; Dickson G; Popplewell L
Hum Gene Ther; 2022 Sep; 33(17-18):923-935. PubMed ID: 35078334
[TBL] [Abstract][Full Text] [Related]
6. Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.
Lu-Nguyen N; Malerba A; Herath S; Dickson G; Popplewell L
Hum Mol Genet; 2021 Jul; 30(15):1398-1412. PubMed ID: 33987655
[TBL] [Abstract][Full Text] [Related]
7. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
[TBL] [Abstract][Full Text] [Related]
8. Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy.
Bittel AJ; Sreetama SC; Bittel DC; Horn A; Novak JS; Yokota T; Zhang A; Maruyama R; Rowel Q Lim K; Jaiswal JK; Chen YW
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759720
[TBL] [Abstract][Full Text] [Related]
9. Influence of
Duranti E; Villa C
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
[TBL] [Abstract][Full Text] [Related]
10. Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy.
Mitsuhashi H; Mitsuhashi S; Lynn-Jones T; Kawahara G; Kunkel LM
Hum Mol Genet; 2013 Feb; 22(3):568-77. PubMed ID: 23108159
[TBL] [Abstract][Full Text] [Related]
11. Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy.
Himeda CL; Jones TI; Virbasius CM; Zhu LJ; Green MR; Jones PL
Mol Ther; 2018 Jul; 26(7):1797-1807. PubMed ID: 29759937
[TBL] [Abstract][Full Text] [Related]
12. Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development.
van den Heuvel A; Mahfouz A; Kloet SL; Balog J; van Engelen BGM; Tawil R; Tapscott SJ; van der Maarel SM
Hum Mol Genet; 2019 Apr; 28(7):1064-1075. PubMed ID: 30445587
[TBL] [Abstract][Full Text] [Related]
13. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene.
Snider L; Geng LN; Lemmers RJ; Kyba M; Ware CB; Nelson AM; Tawil R; Filippova GN; van der Maarel SM; Tapscott SJ; Miller DG
PLoS Genet; 2010 Oct; 6(10):e1001181. PubMed ID: 21060811
[TBL] [Abstract][Full Text] [Related]
14. Antisense targeting of 3' end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach.
Marsollier AC; Ciszewski L; Mariot V; Popplewell L; Voit T; Dickson G; Dumonceaux J
Hum Mol Genet; 2016 Apr; 25(8):1468-78. PubMed ID: 26787513
[TBL] [Abstract][Full Text] [Related]
15. RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy.
Wallace LM; Liu J; Domire JS; Garwick-Coppens SE; Guckes SM; Mendell JR; Flanigan KM; Harper SQ
Mol Ther; 2012 Jul; 20(7):1417-23. PubMed ID: 22508491
[TBL] [Abstract][Full Text] [Related]
16. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase A activation inhibits
Cruz JM; Hupper N; Wilson LS; Concannon JB; Wang Y; Oberhauser B; Patora-Komisarska K; Zhang Y; Glass DJ; Trendelenburg AU; Clarke BA
J Biol Chem; 2018 Jul; 293(30):11837-11849. PubMed ID: 29899111
[TBL] [Abstract][Full Text] [Related]
18. Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy.
Mueller AL; O'Neill A; Jones TI; Llach A; Rojas LA; Sakellariou P; Stadler G; Wright WE; Eyerman D; Jones PL; Bloch RJ
Exp Neurol; 2019 Oct; 320():113011. PubMed ID: 31306642
[TBL] [Abstract][Full Text] [Related]
19. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
[TBL] [Abstract][Full Text] [Related]
20. PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle.
Banerji CRS; Panamarova M; Hebaishi H; White RB; Relaix F; Severini S; Zammit PS
Nat Commun; 2017 Dec; 8(1):2152. PubMed ID: 29255294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
